Raising The Standard of Care

While Covid-19 ravaged communities across the globe, it also served as a catalyst for change and innovation within many industries, including telehealth. One major development in this field was the rise of medicinally-supported teletherapy platforms using controlled substances, including psychedelics like ketamine. Due to regulatory developments that are part of an ongoing conversation around the future of telehealth, licensed clinicians can now legally prescribe controlled substances to patients that they are treating virtually.

These advancements have increased access for patients, and given clinicians increasingly more options for where they can practice. But with all of these options, clinicians are faced with the difficult decision of choosing a telehealth partner. 

If you’re a licensed clinician with an interest in practicing psychedelic-assisted psychiatry or psychotherapy, here are a nine questions to consider when choosing a partner:

1. Is there a respected clinical leader involved with firsthand experience delivering ketamine-assisted psychotherapy to patients?
2. Is ketamine being sold as a “magic pill” with little focus on therapy, or is there real focus on the irreplaceable relational therapeutic elements of genuine ketamine-assisted psychotherapy?
3. Are prescribing clinicians encouraged to take a pragmatic approach to dosing with a focus on patient safety?
4. Are patients receiving integration support from licensed psychotherapists with specialized training in psychedelic-assisted psychotherapy?
5. Do clinicians have access to clinical supervision from highly experienced mentors?
6. Will I have access to a peer community and continuing education to gain experience with new modalities?
7. Are there safeguards in place to monitor patients during and after their psychedelic experiences?
8. Is there a rigorous medical intake process in place designed to identify and rule out patients for whom ketamine-assisted psychotherapy is not safe or appropriate?
9. Do I trust this company to make ethical and responsible decisions that are driven by patient outcomes over profit?

There are many factors to consider, but choosing the right partner will give you the knowledge and support you need to practice confidently and ethically using this exciting new modality that is transforming patient lives.

At Innerwell, we are building the gold standard of psychedelic-assisted psychotherapy, and we are looking for innovative, future-oriented experts in psychiatry and therapy to join us in building the future of psychedelic therapy. If you’re a Psychiatric MD, DO, NP, PA, or a licensed therapist, counselor, or social worker, click here to learn more about our unique approach, or apply now.